Akèy › Melanom › Kalifòni › San Francisco
Etid klinik pou Melanom nan San Francisco, CA
22 etid pou Melanom ap chèche patisipan nan sit nan ak bò kote San Francisco (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Ap rekriteFaz 2
- UCSF Medical Center at Mission Bay ( Site 4044), San Francisco
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Ap rekriteFaz 3
- University of California San Francisco (UCSF), San Francisco
Intratumoral N17350 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of California, San Francisco, San Francisco
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Ap rekriteFaz 2
- Local Institution - 0096, San Francisco
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of California-San Fransisco, San Francisco
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Ap rekriteFaz 1
- University of California San Francisco, San Francisco
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Ap rekriteFaz 1/2
- University of California San Francisco, San Francisco
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- UCSF Medical Center-Mission Bay, San Francisco
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- UCSF Medical Center-Mission Bay, San Francisco
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Ap rekriteFaz 2
- University of California, San Francisco, San Francisco
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Ap rekriteFaz 3
- UCSF Wayne and Gladys Valley Center for Vision, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Ap rekriteFaz 1/2
- University of California San Francisco (UCSF), San Francisco
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Ap rekriteFaz 2/3
- UCSF, San Francisco
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Ap rekriteFaz 1
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Kaiser Permanente-San Francisco, San Francisco
ACTengine® IMA203 Combined With mRNA-4203
Ap rekriteFaz 1
- University of California San Francisco, San Francisco
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Ap rekriteFaz 2
- California Pacific Medical Center - Sutter Health, San Francisco
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
Ap rekriteEtid obsèvasyon
- University of California, San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, San Francisco
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Ap rekriteFaz 2
- University of California, San Francisco (UCSF), San Francisco
Etid Melanom nan lòt vil
- Houston, TX59 etid
- New York City, NY38 etid
- Los Angeles, CA34 etid
- Nashville, TN33 etid
- Pittsburgh, PA31 etid
- Boston, MA26 etid
- Philadelphia, PA23 etid
- Atlanta, GA21 etid
- Durham, NC21 etid
- St. Louis, MO21 etid
- Columbus, OH21 etid
- Salt Lake City, UT21 etid
Lòt etid nan San Francisco
- Kansè pwostat45 etid
- Kansè nan tete43 etid
- Kansè Poumon ki pa ti selil36 etid
- Kansè (tout kalite)35 etid
- Ensifizyans kadyak29 etid
- Kansè Metastatik28 etid
- Kansè poumon23 etid
- Kansè pankreyas20 etid
- Kansè ovè19 etid
- Kansè kolorektal18 etid
- Maladi kadyovaskilè18 etid
- Gliyoblastòm17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.